>Biotinylated Human Siglec-2 / CD22 Protein, Fc Tag, Avi Tag
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).
The protein has a calculated MW of 103.9 kDa. The protein migrates as 115-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
Biotinylated Human Siglec-2, Fc Tag, Avi Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Anti-Human CD22 MAb at 0.5 μg/mL (100 μL/well) can bind Biotinylated Human Siglec-2, Fc Tag, Avi Tag (Cat. No. SI2-H82F8) with a linear range of 1-16 ng/mL (QC tested).
293 cells were transfected with anti-CD22-scFv and RFP tag. 2e5 of the cells were first stained with B. Biotinylated Human Siglec-2 / CD22 Protein, Fc Tag, Avi Tag (Cat. No. SI2-H82F8, 10ug/ml) and C. Biotinylated Protein Control, followed by FITC Streptavidin. A. Non-transfected 293 cells and C. Biotinylated Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD22-scFv) expression and FITC was used to evaluate the binding activity of Biotinylated Human Siglec-2 / CD22 Protein, Fc Tag, Avi Tag (Cat. No. SI2-H82F8).
Human T cells were lentivirally transduced with anti-CD19 CAR and cultured for 3 days. Three days post-transduction, 1e6 cells were first incubated with 100ul Biotinylated Human Siglec-2 / CD22 Protein, Fc Tag, Avi Tag (Cat. No. SI2-H82F8, 10ug/ml), washed and then stained with PE Streptavidin. Non-transduced T cells were used as a control for gating of CAR expression. (Data are kindly provided by Cellyan Therapeutics Co. Ltd.)
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrobiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $350.00
Price(USD) : $1380.00
This web search service is supported by Google Inc.